Background: The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age‐related macular degeneration (e‐ AMD). Method: We included twelve eyes of 12 patients with PED secondary to e‐AMD which were not responding to prior anti‐VEGF treatments. An ophthalmic examination and an assessment of PED‐horizontal maximal diameter (PED‐HMD), PED‐maximum high (PED‐MH) and macular neo-vascularization (MNV) flow area (MNV‐FA) by the means of structural optical coherence tomogra-phy (OCT) and OCT Angiography (OCT‐A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection. Results: The mean age of the population of study was 78.4 (SD ± 4.8). The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD ± 8). At the last follow-up visit, the PED‐HMD did not significantly change (p = 0.16; F(DF:1.94, 20,85) = 1.9), the PED‐MH showed a significant reduction [p = 0.01; F(DF:1.31, 14.13) = 6.84.] and the MNV‐FA did not significantly differ (p = 0.1; F(1.97, 21.67) = 2.54) from baseline. No signs of ocular inflammation were observed during follow‐up. Conclusions: A single Brolucizumab injection was able to determine the short‐term effects on PEDs’ anatomical features of eyes with an unresponsive e‐AMD.

Rispoli, M., Eandi, C. M., Di Antonio, L., Kilian, R., Montesel, A., Savastano, M. C., Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age‐related macular degeneration, <<BIOMEDICINES>>, 2021; 9 (6): 668-679. [doi:10.3390/biomedicines9060668] [http://hdl.handle.net/10807/201311]

Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age‐related macular degeneration

Savastano, M. C.
Ultimo
2021

Abstract

Background: The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age‐related macular degeneration (e‐ AMD). Method: We included twelve eyes of 12 patients with PED secondary to e‐AMD which were not responding to prior anti‐VEGF treatments. An ophthalmic examination and an assessment of PED‐horizontal maximal diameter (PED‐HMD), PED‐maximum high (PED‐MH) and macular neo-vascularization (MNV) flow area (MNV‐FA) by the means of structural optical coherence tomogra-phy (OCT) and OCT Angiography (OCT‐A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection. Results: The mean age of the population of study was 78.4 (SD ± 4.8). The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD ± 8). At the last follow-up visit, the PED‐HMD did not significantly change (p = 0.16; F(DF:1.94, 20,85) = 1.9), the PED‐MH showed a significant reduction [p = 0.01; F(DF:1.31, 14.13) = 6.84.] and the MNV‐FA did not significantly differ (p = 0.1; F(1.97, 21.67) = 2.54) from baseline. No signs of ocular inflammation were observed during follow‐up. Conclusions: A single Brolucizumab injection was able to determine the short‐term effects on PEDs’ anatomical features of eyes with an unresponsive e‐AMD.
Inglese
Rispoli, M., Eandi, C. M., Di Antonio, L., Kilian, R., Montesel, A., Savastano, M. C., Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age‐related macular degeneration, <<BIOMEDICINES>>, 2021; 9 (6): 668-679. [doi:10.3390/biomedicines9060668] [http://hdl.handle.net/10807/201311]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/201311
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact